Panel
Financing the Future of Bioscience and Pharma
- The traditional drug development pipeline requires approximately 15 years and exceeds one billion dollars per approved therapy, yet only one in 10,000 discoveries reaches patients, a high attrition rate that has prompted traditional venture capital to retreat from early-stage translational research in favor of de-risked assets closer to profitability.
- New capital models, including non-dilutive funding, crowdfunding, and the JOBS Act allowing raised capital from non-accredited investors, are emerging to lower investment unit sizes and attract patient-passionate funding to bridge the "valley of death" before Phase III clinical trials.
- The Leukemia and Lymphoma Society aims to deploy $20 million in non-dilutive funding to small companies, with a grant program targeting lab-to-clinic transitions within three to five years, having achieved a 30% transition rate for funded projects and securing $500 million in subsequent third-party deal flow for five partner companies.
- Federal initiatives, such as the NIH's Centers for Accelerated Innovation, are developing lab-to-market programs to provide funding for product definition and feasibility studies, aiming to de-risk technologies to attract downstream funders and foster companies with solid business plans capable of generating SBIR funding or feeding into established entities.
- Market predictions foresee a "golden age" of science where the cost of genome sequencing drops to $500 within two years, with 35 million to 85 million 35-year-olds entering the market over the next decade, while the industry anticipates curing cancer and HIV and potentially extending lifespans to several hundred years.
- While 90% of biotech work is expected to occur in the United States and innovative products currently represent less than 1% of U.S. GDP, industry players anticipate applying biotechnology beyond medicine to energy and food production as large pharmaceutical companies restructure to become smaller and more focused on innovation.
- Significant risks include the high probability of early-stage research failure and the loss of good science if financing is unavailable, though the FDA's new breakthrough status designation and patient-driven advocacy aim to accelerate approvals for unmet medical needs, particularly given that 50% of newly diagnosed blood cancer patients survive less than five years.
- Future financial expectations indicate that public markets and early IPOs can fill transitional medicine funding gaps, with 85 new biotech companies founded last year and 500 more expected in the next five years, potentially freeing up pent-up capital from large company R&D budgets to support the pipeline before late-stage development.